Irfan Ahmer, George Jordan, Obiarinze Ruth, Porterfield John, Barker Andrew, Chen Herbert, Lindeman Brenessa, Fazendin Jessica, Reddy Sushanth
Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Anesthesia, University of Alabama at Birmingham, Birmingham, AL, USA.
Surg Pract Sci. 2022 Nov 5;11:100142. doi: 10.1016/j.sipas.2022.100142. eCollection 2022 Dec.
The use of pre- and intra-operative vasoactive agents for improved blood pressure control has transformed the outcomes following pheochromocytoma (PC) resection. The first agent utilized was phenoxybenzamine, but selective alpha-1 antagonists (SAA) and calcium channel antagonists (CCA) have also been used with success. We sought to define the relationship between pre-operative treatment and intra-operative hemodynamics associated with each of these agents in patients with PC.
A retrospective, single-institution review of patients >18 years with resected PC from 1996-2020 was performed. Pre-operative blockade was at the discretion of the treating providers. Adequacy of pre-operative blockade was determined by the attending surgeon prior to proceeding with PC resection. To determine the effectiveness of pre-operative blockade during surgery, vital signs throughout the operation were examined.
The final dataset included 166 patients. Phenoxybenzamine (55%) and SAA (24%) were the most commonly used pre-operative medications but phenoxybenzamine use decreased over time. Patients who experienced a hypertensive crisis had a higher initial systolic blood pressure and were older. There was no predilection for developing a hypertensive crisis based on race, sex, tumor size or type of pre-operative medication used. Patients in the early group (2010-2015) were found to have more pronounced hemodynamic instability when compared to patients in the late group (2016-2020).
Although there are no demonstrated differences between antihypertensives, the prescription pattern has evolved away from phenoxybenzamine. However, as this is transition happening, patients exhibit better hemodynamic control. We hypothesize that this is due to greater experience by the intra-operative team.
使用术前和术中血管活性药物来改善血压控制,已改变了嗜铬细胞瘤(PC)切除术后的治疗结果。最初使用的药物是酚苄明,但选择性α-1拮抗剂(SAA)和钙通道拮抗剂(CCA)也已成功使用。我们试图确定PC患者术前治疗与这些药物各自相关的术中血流动力学之间的关系。
对1996年至2020年期间年龄大于18岁且已切除PC的患者进行了一项单机构回顾性研究。术前阻滞由治疗医生自行决定。术前阻滞的充分性由主刀医生在进行PC切除术前确定。为了确定术前阻滞在手术期间的有效性,对整个手术过程中的生命体征进行了检查。
最终数据集包括166例患者。酚苄明(55%)和SAA(24%)是最常用的术前药物,但酚苄明的使用随时间减少。经历高血压危象的患者初始收缩压较高且年龄较大。基于种族、性别、肿瘤大小或所使用的术前药物类型,没有发生高血压危象的倾向。与晚期组(2016 - 2020年)的患者相比,早期组(2010 - 2015年)的患者血流动力学不稳定更为明显。
尽管抗高血压药物之间没有明显差异,但处方模式已从酚苄明转变。然而,随着这种转变的发生,患者的血流动力学控制更好。我们推测这是由于术中团队经验更丰富。